Merck, known as MSD outside of the United States and Canada, announced that the company has opened enrollment in its new phase 3 clinical program with investigational once-daily islatravir 0.25 mg in combination with doravirine 100 mg (DOR/ISL) for the treatment of HIV-1 infection.
